Acadian Asset Management
ACRV icon

Acadian Asset Management’s Acrivon Therapeutics ACRV Stock Holding History

Acadian Asset Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
1,165,119
+319,146
+38% +$542K ﹤0.01% 1068
2026
Q1 		$1.18M Buy
845,973
+264,765
+46% +$462K ﹤0.01% 1108
2025
Q4 		$1.4M Buy
581,208
+489,204
+532% +$1.06M ﹤0.01% 1016
2025
Q3 		$165K Buy
+92,004
New +$129K ﹤0.01% 1424

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management's ACRV Position: Q2 2026 in Review

Acadian Asset Management increased its Acrivon Therapeutics (ACRV) stake by 38% in Q2 2026, buying an estimated $542K and bringing the position to 1,165,119 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Acadian Asset Management first reported a position in ACRV in Q3 2025 and has held it in 4 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Acadian Asset Management held 1,165,119 shares of Acrivon Therapeutics worth $2.07M as of Q2 2026.
  • Acadian Asset Management bought 319,146 Acrivon Therapeutics shares in Q2 2026, an estimated $542K.
  • Acrivon Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1068 holding.
  • Acadian Asset Management first reported a position in Acrivon Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.